New Drug Approvals

APRIL 19, 2025

This has a positive impact on the treatment of patients when reduction of heart rate without decrease in arterial blood pressure is desired. [9] Treatment of phenol 143 with bromo epoxide 144 in the present of K2CO3 afforded ether 145 in 76% yield. 9] It is used as landiolol hydrochloride.

FDA

Codon

JULY 14, 2025

Ancient History: Antiquity to 1763 AD When I was in medical school in 2007, I learned that willow bark tea has been used for thousands of years to treat pain and fever. He treated fifty people over five years, all of whom he said were either cured or helped by the treatment. Join Asimov Press. 4 A reproduction of the Ebers Papyrus.

Treatment

New Drug Approvals

JULY 18, 2025

3] It was discovered for the treatment of hepatitis C [4] and has since been investigated for use against other viral diseases such as AIDS and COVID-19 , [2] [5] for which it was granted conditional approval in China. [6] 6] [7] Azvudine was first discovered in 2007. [8] Example 9 Weigh 4.82 2024, 67, 4376−4418 Azvudine (1).

RNA

Fierce BioTech

MAY 2, 2024

Robert Barrow, Chief Executive Officer of MindMed | Generalized anxiety disorder afflicts millions however, the latest treatment was approved in 2007. Now MindMed is advancing a new treatment paradigm.

Treatment

Drug Target Review

JANUARY 25, 2024

These findings offer a novel strategy for developing targeted treatments for triple-negative breast cancer, which currently has no approved options. The team also observed that the drug prevented in vitro cancer stem cells from self-renewing, which is a characteristic of aggressive cancer cells that supports treatment resistance.

Treatment

Drug Target Review

APRIL 4, 2024

Treatment with mesdopetam counteracted both these features of the psychosis model, ie, restored normal levels of synchronisation and reduced HFOs. In rodents, non-human primates, as well as humans, long-term treatment with levodopa has been associated with an increase in dopamine D3 receptor expression.

Disease

Drug Target Review

NOVEMBER 27, 2023

In cancer, the eIF4F complex becomes dysregulated, leading to the excessive production of these proteins, which contribute to tumour formation and resistance to treatment. STRIs represent a fundamentally different approach to cancer therapy compared to traditional treatments like chemotherapy, radiation therapy, and targeted therapies.

Molecular Biology

Drug Target Review

NOVEMBER 17, 2023

Only three of the CAR-NK studies were for the treatment of solid tumours. By themselves, the NK cells showed limited efficacy, but anti-tumour efficacy was observed with co-treatment regimens (eg, monoclonal antibodies, haematopoietic stem cell transplants, whole body irradiation) and multiple dosing (tolerated well by patients).

Therapies

New Drug Approvals

SEPTEMBER 8, 2024

5 On August 14, 2024, seladelpar was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis, 6 which is a condition associated with aberrant bile acid metabolism. 2007 Jul 15;17(14):3855-9. 2007 Jul 15;17(14):3855-9. Epub 2007 May 10. 1] It is used as the lysine dihydrate salt. [1]

FDA

The Pharma Data

DECEMBER 1, 2020

Rapid and substantialimprovement in depressive symptoms achieved by 44% of patients at 2 weeks, 67% at 6 weeks (MADRS response), and sustained with long-term treatment. points at Week 6 (primary timepoint), with AXS-05 treatment. points at Week 6 (primary timepoint), with AXS-05 treatment. NEW YORK, Dec.

Treatment

Broad Institute

AUGUST 25, 2023

TEST: The Stanley Center for Psychiatric Research - History By Maria Nemchuk August 25, 2023 Breadcrumb Home TEST: The Stanley Center for Psychiatric Research - History The Stanley Center was launched in 2007 with transformative support from the philanthropists Ted and Vada Stanley, through the Stanley Medical Research Institute.

Research

Drug Target Review

JUNE 19, 2024

Our goal is to stand on the shoulders of giants and advance this exciting and new field of medicine, so that it can deliver valuable treatments to patients. How do you envision the future of cell therapy and its potential impact on medical treatments and healthcare? Could you give us an overview of the Lineage platform?

Therapies

New Drug Approvals

OCTOBER 12, 2024

2007 ; Kocis et al., ALZ-801 is an advanced and markedly improved candidate for the treatment of alzheimer’s disease. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer’s Disease. 2018; 32(9): 849–861. [2]. Hey JA, et al. Clin Pharmacokinet.

Pharmacokinetics

The Pharma Data

SEPTEMBER 28, 2020

The NHS is facing a “triple whammy” of rising Covid-19 cases, a major backlog in treatment and reduced capacity due to infection-control measures, according to health bosses. The NHS bosses also called on ministers to be “honest and realistic” about waiting lists for treatment.

Nurses

The Pharma Data

JUNE 25, 2021

protofibril antibody for the treatment of Alzheimer’s disease (AD). 1 The proof-of-concept Study 201 explored the impact of treatment with lecanemab on reducing brain amyloid beta (A?) Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for lecanemab (BAN2401), an investigational anti-amyloid beta (A?)

Disease

The Pharma Data

SEPTEMBER 10, 2020

More than two million people on the waiting list – half the total – have been waiting more than 18 weeks, the highest since records began in 2007. But there are some encouraging signs, with treatments happening in hospitals on the increase. Some 83,000 have waited over a year, up from 2,000 before the pandemic.

Hospitals

Drug Target Review

NOVEMBER 1, 2023

The mission of the CCDD is to discover novel small-molecule therapeutics for the treatment of cancer and progress them to hypothesis testing phase 1 clinical trials. I work in the Centre for Cancer Drug Discovery (CCDD) at The Institute of Cancer Research in London, which is an academic drug discovery centre.

Fragment Screening

New Drug Approvals

JANUARY 31, 2024

Sotuletinib (BLZ945) is an experimental drug in development for the treatment of amyotrophic lateral sclerosis (ALS). 18, 2007 and published as WO2007/121484 on Oct. “Emerging clinical investigational drugs for the treatment of amyotrophic lateral sclerosis” Expert Opinion on Investigational Drugs.

Small Molecule

FDA Law Blog: Biosimilars

JULY 11, 2023

Approved in 2007 for the long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy, with several indications added in the subsequent years, Somatuline Depot is a synthetic octapeptide available as ready-to-use prefilled syringes for deep subcutaneous injection.

FDA

Common Sense for Drug Policy Blog

SEPTEMBER 9, 2023

Even among calls for a public health approach to opioids in North America, definitions range from those narrowly focused on population-level prevention via surveillance and research ( Joranson & Gilson, 2006 ) to expansive ones that include a commitment to the principles of social justice, human rights, and equity ( Emerson & Haden, 2021 ).

Treatment

The Pharma Data

JANUARY 18, 2021

FDA advisory committees recommended just 50 percent of the 18 new therapies and indications they reviewed in 2020, the lowest rate since 2007, and the agency seems to be reserving the panels for more problematic applications, according to Prevision Policy, a Washington, D.C.-based based research firm.

FDA

New Drug Approvals

JUNE 26, 2025

1] PATENT US 217370 [link] [link] [link] Medical uses Acoltremon was approved for medical use in the United States in May 2025, for the treatment of signs and symptoms associated with dry eye disease. [2] 2007 Mar;41(3):285-94. 5] References ^ Jump up to: a b [link] ^ “Novel Drug Approvals for 2025” U.S. . 28 May 2025.

FDA

The Pharma Data

JULY 29, 2021

Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab Following 18 Months of Treatment in the Open-Label Extension of the Phase 2 Proof of Concept Study at 2021 Alzheimer’s Association International Conference (AAIC) . 42/40 ratio, brain amyloid by PET and treatment Low values of plasma A?42/40

Clinical Trials

Drug Target Review

FEBRUARY 7, 2024

The gene expression ‘transcriptome’ from the cell type we studied has a p-value that is better than this by a factor of 500,000x. How do the findings of the research reveal the potential treatments options for COVID-19, particularly in terms of managing excessive inflammation and targeting specific enzymes?

RNA

The Pharma Data

OCTOBER 15, 2020

health data to track outcomes for nearly 15,000 men diagnosed with breast cancer between 2007 and 2016. Timely and aggressive treatment seemed key to long-term survival, too. Ellington and colleagues used U.S.

Treatment

Conversations in Drug Development Trends

FEBRUARY 28, 2023

95% of rare diseases don’t have a treatment approved and won’t anytime soon. Miraculously, there was an approved treatment. Over the next few decades, that drug made its way through clinical trials, securing approval in 2007—just 36 months before Rob was diagnosed in 2010. Uplifting Athletes (UA) is on a mission to change that.

Clinical Trials

Drug Target Review

AUGUST 10, 2023

Metastasis is the most lethal attribute of cancer cells and clinical decisions regarding treatment are based largely upon the likelihood of developing metastases. Implications for cancer therapeutics and beyond These findings have wide-ranging implications for cancer treatment and cell biology research. Available from: [link]

Cell Biology

The Pharma Data

DECEMBER 8, 2020

And it makes sense, he added, given that “the suicide rate among young people in the United States went up 60% from 2007 to 2018.” These disclosures helped normalize mental health issues and validated getting treatment as a socially acceptable action.”

Doctors

Conversations in Drug Development Trends

MAY 23, 2024

These therapies offer improved safety and high potency with fewer side effects than traditional treatments. Navigating Advanced Therapy Medicinal Products (ATMPs) in the EU: Regulatory Challenges : The EU has an overall regulatory framework for ATMPs , Regulation (EC) No 1394/2007. However, they also bring unique regulatory challenges.

Trials

The Pharma Data

JUNE 1, 2022

Anderson has led the team of infectious disease biologists that validated and delivered to an emergency use authorization PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets), Pfizer’s novel COVID-19 oral treatment. Dr. Anderson joined Pfizer via Wyeth in 2007.

Vaccine

Drug Target Review

JULY 3, 2024

Additionally, in the SeaBeLife project, we explored the biotechnological applications of unique bioinspired molecules, paving the way for new possibilities in treating those severe diseases without effective treatment. In 2007, she co-founded Hemarina, a pioneer in marine therapeutic oxygen carriers.

Research

Drug Target Review

SEPTEMBER 26, 2023

This will be achieved by inducing a seizurogenic phenotype using a known seizurogenic compound, and then determining if these changes are reduced by application epilepsy treatments. 2007 Jul;7(4):348–54. 26 Outside of drug safety, we also plan to adapt our model to anti-epileptic drug discovery. Brain Behav Evol. 2000 Jun;55(6):287–99.

Drugs

The Pharma Data

OCTOBER 6, 2021

Early-stage research suggests potential to prevent and treat all dengue serotypes With no treatments available, dengue infects up to 400 million people each year and the pace of outbreaks is increasing. [1] The Janssen dengue compound discovery program started in 2007.

Virus

The Pharma Data

JANUARY 25, 2021

Rosie arrived in June 2007. “The typical treatments didn’t work, and she always took longer to recover.” Two days later, Rosie underwent her first surgery. After two weeks at home, she went into heart failure and spent the next two months in the cardiac ICU. She had her second open-heart surgery in February 2008.

Doctors

Agency IQ

SEPTEMBER 15, 2023

Background on oral phenylephrine as a nonprescription nasal decongestant Phenylephrine is an alpha-1 adrenergic agonist that is approved as a nonprescription oral treatment for temporary relief of nasal congestion , sinus congestion and pressure. The FDA will follow these procedures for both agency-initiated operations (e.g.,

Science

The Pharma Data

NOVEMBER 22, 2020

This patent completes the Ezeprogind related patents granted in the USA for composition of matter (US 9,562,018) and therapeutic uses in the treatment of Alzheimer’s and Parkinson’s diseases (US 10,537,569). Alzprotect is financed by the XERYS fund (Paris). About Alzprotect.

Drugs

The Pharma Data

OCTOBER 1, 2021

Safety was evaluated by analyzing the frequency of treatment-emergent adverse events (TEAE). Approved indications include CE MRI of the CNS, CE-MRA (2003), CE MRI of the liver and kidneys (2007), and CE MRI of all body regions (whole body, 2012) within the EU and other countries. Gadobutrol injection was first approved within the U.S.

Clinical Trials